Hepatobiliary Neoplasia SIG: New Therapies in HCC: Mechanisms of Action and Indications

4.5 (2 votes)

Recorded On: 11/11/2018

This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.

Jessica Zucman-Rossi

Augusto Villanueva

Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

Josep Llovet

Anthony El-Khoueiry

Richard Finn

Key:

Complete
Failed
Available
Locked
Linking cancer drivers to targeted therapies in HCC
Open to view video.
Open to view video. Presenter: Jessica Zucman-Rossi
Mechanisms of action of drugs effective in HCC
Open to view video.
Open to view video. Presenter: Augusto Villanueva
New drugs effective in the systemic treatment of HCC
Open to view video.
Open to view video. Presenter: Josep Llovet
Advances in immunotherapy for HCC
Open to view video.
Open to view video. Presenter: Anthony El-Khoueiry
The place of novel therapies in the AASLD guidelines for HCC
Open to view video.
Open to view video. Presenter: Richard Finn
Panel Discussion/Q&A
Open to view video.
Open to view video.
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.